The progress made by antibiotic start-up Spero Therapeutics LLC offers a clear example of how the Generating Antibiotic Incentives Now provisions have helped reinvigorate research in the infectious disease space. In an interview with the Pink Sheet, Spero CEO Ankit Mahadevia noted that the GAIN incentives enabled his firm not only to raise about $65m across Series A and B financings, but also will open up an accelerated approval pathway for the firm's novel drugs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?